Mark Gurney, Ph.D. MBA
Dr. Mark Gurney, is the Chairman and CEO of Tetra Discovery Partners. Dr. Gurney previously was Senior Vice President of Drug Discovery and Development for deCODE genetics, Inc. where he led two CRO businesses which grew in annual sales from $13 to $22 million. Dr. Gurney developed 3 Decode compounds through human Phase I clinical trials and also developed a client drug to treat spinal muscular atrophy that was licensed to Pfizer for $70 million and recently entered human Phase II clinical trials. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s disease therapeutics by the global law firm Griffith Hack. He has authored 116 peer-reviewed papers that have been cited over 18,000 times and holds 35 issued patents.
Stephen D. Nimer, M.D.
Dr. Nimer is an expert in treating leukemia and lymphoma. A hematologist, molecular biologist, and bone marrow transplant physician, Dr. Nimer is currently the Director of the Sylvester Comprehensive Cancer Center at the University of Miami, Florida. Dr. Nimer was at Memorial Sloan-Kettering Cancer Center in New York for nearly 20 years. Over the years, Dr. Nimer has conducted extensive clinical and basic science research into the treatment and genetic basis of adult leukemia and bone marrow failure states, defining the regulatory mechanisms that control the production of blood cells and exploring ways to improve the treatment of blood based cancers. He has authored over 200 scientific publications and has received numerous awards for his research, including the prestigious Irma T. Hirschl Career Scientist Award. Dr. Nimer graduated from the Massachusetts Institute of Technology in 1975, and received his M.D. degree with honors from the University of Chicago of Medicine in 1979. He completed training in Internal Medicine and Hematology/Oncology at the UCLA School of Medicine, and joined the faculty there in 1986, before moving to Memorial Sloan-Kettering in 1993.
Claes Wahlestedt, Ph.D., M.D.
Dr. Wahlestedt is the Leonard M. Miller Professor at the University of Miami and is spearheading a range of drug discovery and translational efforts in his roles as Associate Dean and Center Director for Therapeutic Innovation. He is the author of more than 200 research papers and has ongoing research projects concerning epigenetics, mammalian transcriptomics, noncoding RNAs, neuroscience, cancer and drug discovery across several therapeutic areas. A native of Sweden, Claes obtained his M.D. and Ph.D. degrees from Lund University, and then went on to develop an international career in academia as well as in the pharmaceutical industry. Before joining the University of Miami, Dr. Wahlestedt was a professor and director of neuroscience discovery at the new Florida campus of The Scripps Research Institute (2005-2011). Before that he was an endowed professor and chair of the Department for Genomics and Bioinformatics at the Karolinska Institute in Stockholm (1997-2005). Previously, he also directed large drug discovery and biotechnology teams in the pharmaceutical industry for Astra-Zeneca, Pharmacia & Upjohn, and Pharmacia Corporation. His most recent biotechnology start-up was CURNA Inc. which was acquired by OPKO Health in 2011.